WCA
TPTX

Windsor Creek Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Windsor Creek Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7,845
Closed -$489 – 211
2019
Q4 		$489 Buy
7,845
+2,170
+38% +$103K 0.13% 98
2019
Q3 		$213K Buy
+5,675
New +$247K 0.05% 134

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Windsor Creek Advisors's TPTX Position: Q1 2020 in Review

Windsor Creek Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2020, closing a stake of 7,845 shares — an estimated $489 sold.

Windsor Creek Advisors first reported a position in TPTX in Q3 2019 and held it in 2 quarters. The position peaked at $213K in Q3 2019. 119 funds tracked by Wall St. Rank hold TPTX as of Q1 2020.

  • Windsor Creek Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Windsor Creek Advisors sold 7,845 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $489.
  • Windsor Creek Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Windsor Creek Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $213K in Q3 2019.
  • 119 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Windsor Creek Advisors's 13F filing for Q1 2020, filed 12 May 2020.